Crossref
IgM Pemphigoid With Anti‐ BP180 C‐Terminal Autoantibodies Developing After Pembrolizumab and Enfortumab Vedotin Therapy
The Journal of Dermatology · 18.11.2026
DOI: 10.1111/1346-8138.70578 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 18.11.2026. Verfasst von Hiroshi Koga und 4 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Koga, H., Ohzono, A., Tsutsumi, M., Maeda, S., & Ishii, N. (2026). IgM Pemphigoid With Anti‐ BP180 C‐Terminal Autoantibodies Developing After Pembrolizumab and Enfortumab Vedotin Therapy. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70578
Vancouver
Koga H, Ohzono A, Tsutsumi M, Maeda S, Ishii N. IgM Pemphigoid With Anti‐ BP180 C‐Terminal Autoantibodies Developing After Pembrolizumab and Enfortumab Vedotin Therapy. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70578
BibTeX
@article{Koga2026,
author = {Koga, Hiroshi and Ohzono, Ayaka and Tsutsumi, Masahiro and Maeda, Sakura and Ishii, Norito},
title = {IgM Pemphigoid With Anti‐ BP180 C‐Terminal Autoantibodies Developing After Pembrolizumab and Enfortumab Vedotin Therapy},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70578}
}
EUVIMED